Dr William Matsui speaks about plasma cell biology and how this affects cancer growth. In multiple myeloma, malignant plasma cells make up the vast majority of tumour cells and are thought to be responsible for tumour growth. Dr Matsui speaks about the aims and challenges facing his work evaluating if rituximab can be used to treat multiple myeloma and looking to see if signalling pathways can be targeted to prevent cancer development.